• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gold Falls Sharply; US Composite PMI Surges In May

    5/23/24 12:01:36 PM ET
    $BCYC
    $BNZI
    $CYTK
    $ELF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $BCYC alert in real time by email

    U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Thursday.

    The Dow traded down 0.65% to 39,414.01 while the NASDAQ rose 0.84% to 16,942.51. The S&P 500 also rose, gaining, 0.24% to 5,319.63.

    Check This Out: How To Earn $500 A Month From Ross Stores Stock Ahead Of Q1 Earnings

    Leading and Lagging Sectors

    Information technology shares rose by 1.3% on Thursday.

    In trading on Thursday, real estate shares fell by 1.1%.

    Top Headline

    The S&P Global manufacturing PMI rose to 50.9 in May from 50 in April, while services PMI climbed to 54.8 in May from 51.3.

    The S&P Global composite PMI jumped to 54.4 in May compared to 51.3 in April, and topping market estimates of 51.1.

    Equities Trading UP
                           

    • OneMedNet Corporation (NASDAQ:ONMD) shares shot up 145% to $1.1699 after the company highlighted a ‘five-fold expansion’ of its iRWD network and platform.
    • Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) got a boost, surging 18% to $25.34 after the company announced a $555 million private placement equity financing.
    • e.l.f. Beauty, Inc. (NYSE:ELF) shares were also up, gaining 19% to $185.34 after the company reported better-than-expected fourth-quarter earnings.

    Equities Trading DOWN

    • Banzai International, Inc. (NASDAQ:BNZI) shares dropped 20% to $0.1820. Banzai announced pricing of $2.5 million public offering.
    • Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) were down 17% to $49.10. Cytokinetics priced its public offering of 9,803,922 common stock at $51 per share.
    • Triumph Group, Inc. (NYSE:TGI) was down, falling 12% to $13.28 after the company reported fourth-quarter FY24 results.

    Also Check This Out: Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A ‘Terrific Spec’

    Commodities

    In commodity news, oil traded down 0.1% to $77.52 while gold traded down 1.8% at $2,348.80.

    Silver traded down 3.1% to $30.515 on Thursday, while copper fell 0.8% to $4.8115.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.08%, Germany's DAX fell 0.17% and France's CAC 40 slipped 0.10%. Spain's IBEX 35 Index fell 0.36%, while London's FTSE 100 fell 0.45%.

    The HCOB Eurozone services PMI came in unchanged at 53.3 in May, while manufacturing PMI rose to 47.4 in May 2024, recording the highest level in 15 months.

    The S&P Global UK composite PMI fell to 52.8 in May, from 54.1 in April. The Germany composite PMI climbed to 52.2 in May, notching the strongest reading in a year. France composite PMI declined to 49.1 in May compared to 50.5 in the previous month.

    Asia Pacific Markets

    Asian markets closed mixed on Thursday, with Japan's Nikkei surging 1.26%, China's Composite Index dipping 1.33%, Hong Kong's Hang Seng Index falling 1.70% and India's S&P BSE Sensex gaining 1.36%.

    The annual inflation rate in Hong Kong eased to 1.1% in April versus 2% a month ago and compared to market estimates of 2.1%. The HSBC India composite PMI rose to 61.7 in May 2 from 61.5 a month ago. The au Jibun Bank Japan composite PMI increased to 52.4 in May from 52.3 a month ago.

    Economics

    • The Chicago Fed National Activity Index declined to -0.23 in April versus a revised reading of -0.04 in the prior month.
    • U.S. initial jobless claims declined by 8,000 to 215,000 in the week ending May 18, compared to market estimates of 220,000.
    • The S&P Global manufacturing PMI rose to 50.9 in May from 50 in April, while services PMI climbed to 54.8 in May from 51.3.
    • The S&P Global composite PMI jumped to 54.4 in May compared to 51.3 in April, and topping market estimates of 51.1.
    • Sales of new single-family houses fell 4.7% month-over-month to an annualized rate of 634K in April.
    • U.S. natural-gas supplies increased 78 billion cubic feet during the week ended May 17.

    Now Read This: Top 5 Financial Stocks You May Want To Dump In Q2

    Get the next $BCYC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCYC
    $BNZI
    $CYTK
    $ELF

    CompanyDatePrice TargetRatingAnalyst
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    e.l.f. Beauty Inc.
    $ELF
    1/23/2026$110.00Buy
    Citigroup
    e.l.f. Beauty Inc.
    $ELF
    1/14/2026$110.00Buy
    Jefferies
    Cytokinetics Incorporated
    $CYTK
    12/18/2025$95.00Neutral → Buy
    Goldman
    Bicycle Therapeutics plc
    $BCYC
    11/24/2025$19.00Hold
    Truist
    e.l.f. Beauty Inc.
    $ELF
    11/6/2025$100.00Overweight → Neutral
    Piper Sandler
    Bicycle Therapeutics plc
    $BCYC
    10/31/2025$11.00Outperform → Sector Perform
    RBC Capital Mkts
    e.l.f. Beauty Inc.
    $ELF
    10/8/2025$134.00 → $170.00Overweight
    Morgan Stanley
    More analyst ratings

    $BCYC
    $BNZI
    $CYTK
    $ELF
    SEC Filings

    View All

    Banzai International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Banzai International, Inc. (0001826011) (Filer)

    2/13/26 5:25:56 PM ET
    $BNZI
    Computer Software: Prepackaged Software
    Technology

    SEC Form AW filed by Banzai International Inc.

    AW - Banzai International, Inc. (0001826011) (Filer)

    2/13/26 4:08:10 PM ET
    $BNZI
    Computer Software: Prepackaged Software
    Technology

    SEC Form S-8 filed by Banzai International Inc.

    S-8 - Banzai International, Inc. (0001826011) (Filer)

    2/13/26 4:05:40 PM ET
    $BNZI
    Computer Software: Prepackaged Software
    Technology

    $BCYC
    $BNZI
    $CYTK
    $ELF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics'

    2/12/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), today announced record bookings in 2025 of data-delivery agreements totaling $2.79 million of contract value, exceeding 2024 bookings by more than four times (4X). The milestone reflects increasing deal size, strong enterprise demand, and meaningful progress toward a recurring subscription model. The Company also provides an update on product offering heading into 2026. 2025 Booking Highlights Total Bookings: $2.79 million in contract value signed in 2025, 4.1X more than prior fiscal yearLarger Deal Sizes:

    2/12/26 9:00:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    e.l.f. Beauty Announces Third Quarter Fiscal 2026 Results

    – Delivered 38% Net Sales Growth – – Raises Fiscal 2026 Outlook – e.l.f. Beauty (NYSE:ELF) today announced results for the three and nine months ended December 31, 2025. "Our Q3 results, which included 130 basis points of market share gains for our namesake e.l.f. Cosmetics brand and a record-breaking launch of rhode in Sephora in the U.K., are a continuation of the consistent, category-leading growth we've delivered over the past 28 quarters," said Tarang Amin, e.l.f. Beauty's Chairman and Chief Executive Officer. "Our value proposition, powerhouse innovation and disruptive marketing engine continue to fuel our brands. We remain confident in our ability to grow market share and deliv

    2/4/26 4:05:00 PM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    $BCYC
    $BNZI
    $CYTK
    $ELF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Casaburi Eric bought $39,262 worth of shares (20,475 units at $1.92) and was granted 90,000 shares (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:54:45 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BCYC
    $BNZI
    $CYTK
    $ELF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BCYC
    $BNZI
    $CYTK
    $ELF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by Director Schofield Kent

    4 - Banzai International, Inc. (0001826011) (Issuer)

    2/12/26 9:19:25 PM ET
    $BNZI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Director Boggs Paula

    4 - Banzai International, Inc. (0001826011) (Issuer)

    2/12/26 8:44:10 PM ET
    $BNZI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Director Ward Mason

    4 - Banzai International, Inc. (0001826011) (Issuer)

    2/12/26 4:30:04 PM ET
    $BNZI
    Computer Software: Prepackaged Software
    Technology

    Barclays resumed coverage on Cytokinetics with a new price target

    Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00

    1/28/26 7:16:37 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on e.l.f. Beauty with a new price target

    Citigroup initiated coverage of e.l.f. Beauty with a rating of Buy and set a new price target of $110.00

    1/23/26 8:18:55 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Jefferies resumed coverage on e.l.f. Beauty with a new price target

    Jefferies resumed coverage of e.l.f. Beauty with a rating of Buy and set a new price target of $110.00

    1/14/26 8:40:46 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    $BCYC
    $BNZI
    $CYTK
    $ELF
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    e.l.f. Lands at ULTA Beauty Mexico, Expanding Accessibility to the Best of Beauty for Every Eye, Lip, and Face

    e.l.f.'s presence is growing following successful market launch in 2024 e.l.f. Beauty (NYSE:ELF), the bold disruptor with a kind heart, continues to expand its e.l.f.iverse with its official launch at ULTA Beauty in Mexico, marking the next step of its partnership with the retailer. Beginning today, November 10, 2025, beauty enthusiasts in Mexico can explore the best of e.l.f. Cosmetics and e.l.f. SKIN at all ULTA Beauty stores across the country and on the retailer's e-commerce platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251109144964/en/e.l.f. continues to expand its e.l.f.iverse with its official launch at ULTA

    11/10/25 12:01:00 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Jamieson Wellness Inc. Announces Appointment of New Board Director

    Global CPG and tech executive brings more than 25 years of digital expertise to support the Company's growing e-commerce opportunities Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today the appointment of Gayle Tait to the Company's Board of Directors. "The VMS marketplace is experiencing a shift towards digital and social ecommerce globally," said Tim Penner, Chair of the Board of Jamieson Wellness. "As consumers continue to seek out digital communities to support their health and wellness journeys, understanding this rapidly growing and changing environment is crucial to growing with them. "Gayle has an impressive track record of driving enterpr

    10/21/25 4:05:00 PM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    $BCYC
    $BNZI
    $CYTK
    $ELF
    Financials

    Live finance-specific insights

    View All

    Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics'

    2/12/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

    MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and rever

    12/19/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BCYC
    $BNZI
    $CYTK
    $ELF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

    SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    11/14/24 5:46:12 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

    SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    11/14/24 4:32:50 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care